Efficacy and safety of third-line treatment with anlotinib in patients with refractory advanced non-small-cell lung cancer (ALTER-0303): a randomised, double-blind …
B Han, K Li, Q Wang, Y Zhao, L Zhang, J Shi… - The Lancet …, 2017 - thelancet.com
Background Anlotinib hydrochloride, an oral tyrosine kinase inhibitor targeting VEGFR,
FGFR, PDGFR, and c-kit, showed promising efficacy in a phase 2 study. Here, we evaluated …
FGFR, PDGFR, and c-kit, showed promising efficacy in a phase 2 study. Here, we evaluated …
Efficacy and safety of third-line treatment with anlotinib in patients with refractory advanced non-small-cell lung cancer (ALTER-0303): a randomised, double-blind …
B Han, K Li, Q Wang, Y Zhao, L Zhang, J Shi… - The Lancet …, 2017 - Elsevier
Background Anlotinib hydrochloride, an oral tyrosine kinase inhibitor targeting VEGFR,
FGFR, PDGFR, and c-kit, showed promising efficacy in a phase 2 study. Here, we evaluated …
FGFR, PDGFR, and c-kit, showed promising efficacy in a phase 2 study. Here, we evaluated …
Efficacy and safety of third-line treatment with anlotinib in patients with refractory advanced non-small-cell lung cancer (ALTER-0303): a randomised, double-blind …
B Han, K Li, Q Wang, Y Zhao, L Zhang, J Shi… - The Lancet …, 2017 - infona.pl
Anlotinib hydrochloride, an oral tyrosine kinase inhibitor targeting VEGFR, FGFR, PDGFR,
and c-kit, showed promising efficacy in a phase 2 study. Here, we evaluated the efficacy and …
and c-kit, showed promising efficacy in a phase 2 study. Here, we evaluated the efficacy and …